eMETHODS. Cohort Descriptions
A summary of the major cohort characteristics can be found in Table 1 of the manuscript. A detailed description of each cohort is also included below.
Atherosclerosis Risk in Communities (ARIC)
The Atherosclerosis Risk in Communities (ARIC) Study, sponsored by the National Heart, Lung and Blood Institute (NHLBI), is a prospective epidemiologic study conducted in four U.S. African Americans were enrolled in Jackson, Mississippi, and Forsyth County, North Carolina. 2 The current study included 3,402 African-American subjects from ARIC who had provided consent for genetic studies and who had sufficient genetic material and data, all of whom were directly genotyped for rs334.
At each study visit, participants provided information on demographics and medical history, underwent blood pressure measurements and provided blood and/or urine samples. Systolic and diastolic blood pressures (BP) were recorded as an average of two of three seated measurements.
Hypertension was defined as systolic BP≥140 mmHg, diastolic BP≥90 mmHg, or self-reported use of antihypertensive medication. Body mass index (kg/m2) was calculated from weight and height measurements. Diabetes was defined as fasting glucose≥126 mg/dl, nonfasting glucose≥200 mg/dl, self-reported physician diagnosis of diabetes, or self-reported use of oral hypoglycemic medication or insulin. 2 Serum creatinine was measured at ARIC visits 1, 2, 4, and 5 via a modified kinetic Jaffé method.
All values were calibrated to the Cleveland Clinic laboratory. Cystatin C was measured using the Siemens Healthcare Diagnostics BN II System (www.medical.siemens.com) by an immunonephelometric assay from samples collected at visits 2, 4 and 5. 
Jackson Heart Study (JHS)
The JHS is a single-site, prospective, population-based study designed to explore the environmental, behavioral, and genetic factors that influence the development of cardiovascular cohort. Of the enrolled participants, 3,630 were recruited uniquely to JHS and did not participate in ARIC. Overviews of the JHS including the sampling and recruitment, sociocultural, and laboratory methods have been described previously. [5] [6] [7] [8] All of the participants provided written informed consent. Participants were between 35 and 84 years old, and members of the family cohort were ≥ 21 years old when consent for genetic testing was obtained and blood was drawn for DNA extraction.
For the current study, participants who were enrolled in both JHS and ARIC were analyzed as part of the ARIC cohort only. A total of 2,105 subjects were included in the current JHS analysis.
Among these, rs334 was assessed by direct sequencing in 2,063 (98%) and was imputed in the remainder.
The baseline examination consisted of a home interview, self-administered questionnaires, and a clinic visit. Medications taken in the prior 2 weeks were brought to clinic and transcribed verbatim with subsequent coding by a pharmacist. After an overnight fast, anthropometric and seated blood pressure measurements were obtained and venipuncture/urine collection was performed in accordance with the National Committee for Clinical Laboratory Standards. Blood pressure was measured by trained technicians using a Hawksley random zero manometer and determined by the arithmetic average of two readings taken 1 minute apart after a five-minute rest. 9 All baseline participants were requested to contribute a 24-hour urine collection. Because some participants did not agree to the 24-hour urine collection, spot urine collections were later added to the protocol. Urine albumin and creatinine concentrations were obtained for each collection method. Urine albumin was measured using a human albumin kit (Dade Behring, Newark, A total of 8,000 subjects from WHI were included in the current study, of which 567 were directly genotyped for rs334 via sequencing and the rest were imputed. 
Multi-Ethnic Study of Atherosclerosis (MESA)
The MESA study was designed to investigate the correlates of subclinical CVD progression in a longitudinal multi-ethnic cohort free of CVD at baseline. Detailed methods of MESA have been reported previously. 12 Participants were excluded if they had physician-diagnosed cardiovascular disease prior to enrollment, including angina, myocardial infarction, heart failure, stroke or TIA, resuscitated cardiac arrest or a cardiovascular intervention (e.g., CABG, angioplasty, valve replacement, or pacemaker/defibrillator placement). Pre-specified recruitment plans identified four racial/ethnic groups (White European-American, African-American, Hispanic-American, A total of 1,620 subjects were included in the current study, of which 146 were directly genotyped for rs334 via sequencing and the rest were imputed.
Participant characteristics were obtained from data collected at the enrollment visit from physical measures, standardized questionnaires, and laboratory tests. These included demographic information (age, sex, race/ethnicity), medical history, medications, and alcohol, and tobacco use.
Resting blood pressure was determined by taking three measurements with the participant in the 
Coronary Artery Risk Development in Young Adults (CARDIA)
The of Coronary Artery Risk Development in Young Adults (CARDIA) study is a prospective, multi-center study of the natural history and etiology of CVD in a bi-racial population. Study design details have been previously published. 13 Briefly, a cohort of healthy young adults from the community, age 18-30 at the time of enrolment, balanced by race (black and white) and sex A total of 848 subjects from CARDIA were included in the current study, of which 15 were directly genotyped for rs334 via sequencing and the rest were imputed.
At baseline and at years 10, 15, and 20 of study visits, serum creatinine was measured by nephelometry at University of Minnesota. Seventeen years after baseline, a random sample of baseline samples was re-run using the method used at year 15 (N=103). At 23 years after baseline, stored samples from years 10 (N=197), 15 (N=198), and 20 (N=187) were re-run and calibrated to National Institute of Standards and Technology standards as recommended by the National Kidney Disease Education Program Laboratory Working Group. Urine albumin/creatinine ratio was measured from a single, untimed (spot) urine sample collected at examinations at years 10, 15, and 20 using a nephelometric procedure with a specific antialbumin monoclonal antibody, and creatinine was assessed with the Jaffe method. All urine albumin-to-creatinine ratios were expressed in milligrams per gram creatinine. 14 Cystatin C was measured at examination years 10, 15, and 20 from frozen samples by nephelometer using the N Latex Cystatin C kit (Dade Behring, now Siemens). All cystatin C measurements were performed simultaneously at the University of Minnesota (coefficient of variation 4.0%). The assay was calibrated for drift by re-assaying frozen serum samples from 48 participants using the Gentian Cystatin C Immunoassay and calibrated to international standards. Initial cystatin C assays were on average 12% lower prior to calibration.
Genotyping for rs334 sickle cell mutation
Genotype data for rs334 encoding the sickle cell mutation (HBB p.Glu7Val) were obtained using one of 3 methods: custom genotyping, exome sequencing, or by imputation into the remaining sample of African Americans with genome-wide genotyping (Affymetrix 6.0). These methods are detailed further below.
Custom genotyping of rs334 in ARIC cohort
Direct genotype data for the rs334 variant were obtained by custom genotyping from the ARIC study. At ARIC visits, staff drew and processed blood samples, and DNA was isolated using Gold DNA Polymerase and no AmpErase UNG. After an initial step of 10 min at 95ºC, the products were amplified using 50 cycles of 15 s at 92ºC and 1 min at 60ºC. Allele detection and genotype calling were performed using the ABI 7900HT and the Sequence Detection System software (Life Technologies, formerly Applied Biosystems). Quality control measures utilized a blind duplicate program in which 5% of samples were re-genotyped at random.
DNA sequencing had also been performed on 2,768 overlapping individuals using Illumina
HiSeqs after exome capture with NimbleGen's VChrome2.1. Genotypes were derived using Mercury, 15 and sequencing results for HbS and HbC were compared with TaqMan results.
Genotyping of 43 individuals with discordant genotypes (HbS N=36 and HbC N=10; 3 individuals were discrepant at both sites) was repeated and 288 samples that had previously been genotyped were also included to establish clustering patterns. Discrepancies were adjudicated by review of quality control data and re-genotyping to yield the final HbS and HbC classifications.
Exome Sequencing
Exome sequencing was performed through the National Heart, Lung, and Blood Institute 
